Will trametinib cause low blood counts?

Trametinib is a mitomycin kinase (MEK) inhibitor primarily used to treat advanced or metastatic melanoma and non-small cell lung cancer with BRAF V600E or V600K mutations. In clinical application, trametinib may cause a series of side effects, including low blood levels.

Low blood count means that the number of certain cell types in the blood is lower than normal, including white blood cells, red blood cells and platelets. Trametinib may affect the normal function of the hematopoietic system, resulting in a decrease in the number of these cells, resulting in low blood counts.

Specifically, trametinib may cause the following types of low blood counts:

1.Leukopenia (low white blood cell count): Trametinib may cause white blood cell counts to be lower than normal, which may increase a patient's risk for infection. White blood cells are the body's main immune cells, responsible for fighting off foreign pathogens and maintaining immune system function. Therefore, a decrease in white blood cells may make patients more susceptible to infections, and infections may be more severe.

2.Anemia (low red blood cells): Trametinib may also cause anemia, which is a lower than normal number of red blood cells. Anemia can cause patients to feel tired and weak, and may experience other symptoms such as dizziness and shortness of breath. Red blood cells are the main cells that carry oxygen to all parts of the body, so anemia may affect the body's oxygen supply, causing impairment of the functions of various body systems.

3.Thrombocytopenia: Platelets are a type of cell in the blood that are responsible for blood clotting and hemostasis. Trametinib may cause a decrease in platelet counts, which may increase a patient's risk of bleeding. Risks of bleeding include skin bruising, nosebleeds, gum bleeding, etc., and in severe cases, internal bleeding may be life-threatening.

Therefore, during treatment with trametinib, patients need to conduct regular blood tests, monitor blood cell counts, and other related indicators, and promptly report to the doctor if any abnormal symptoms occur. Doctors may adjust the dosage or take other therapeutic interventions based on the patient's specific situation to ensure that the patient's blood indicators are maintained within a safe range and to minimize the adverse effects of treatment.